INTRODUCTION
In this review we examine evidence for autocrine and paracrine growth regulation of normal and malignant mammary epithelium. A particular emphasis is placed on the critical role of secreted growth factors and their receptors.
ENDOCRINE, AUTOCRINE, AND PARACRINE MECHANISMS OF GROWTH REGULATION The development of the complete malignant phenotype depends on interactions between inherited genetic factors, exposure to chemical carcinogens, damaging radiation, oncogenic viruses, and mitogenic hormones, and other promotional agents [ 1] . Experimental animal model systems [2] have allowed considerable insight into the mechanisms of action of these components; however, the exact etiology of any human cancer has not been fully established. The work of Huggins and Clark [3] , linking testicular secretions (androgen) to prostatic carcinoma, and by Beatson [4] , linking ovarian secretions (estrogens) to breast carcinoma, represented critical insights into endocrine-dependent neoplasia. In this section we summarize the potential mechanisms of action of systemic estrogen in the human breast cancer process. We also explore the mechanisms of loss of endocrine control of experimental and clinical breast and lymphatics, and reseeding in distant metastatic sites. It probably also involves both oncogene-and mitogenic-mediated processes.
Estrogens play an obvious and critical role in normal mammary development. They clearly function both as permissive agents for carcinogen action and as true tumor promotors. Women without functioning ovaries essentially never develop breast cancer, and many breast cancers show an estrogen-dependent or responsive phenotype. A major thesis of this review is that estrogens act by inducing production of locally acting hormones. To identify some of these mediators of growth control, reference may be made to a well-established system for rodent fibroblasts in vitro. Smith, Scher, and Todaro, among others, identified "restriction points" in the cell cycle of "normal" (but immortalized) fibroblasts. Various polypeptide growth factors abrogate these restriction points and allow the cell cycle to progress [19] . Platelet-derived growth factor (PDG F) allows cells to pass a restriction point in early G1. As PDGF acts to initiate the cell cycle, several genes known as proto-oncogenes are sequentially induced. Among these are c-fos and c-myc in the nucleus, and c-ras in the plasma membrane [20] . Epidermal growth factor (EGF) or the related transforming growth factor (TGFa), act later, while insulin-like growth factor I (IGF-I), also known as somatomedin C, and other hormones act still later in G,. One growth factor may induce another one, which acts further along in the cell cycle. For example, human diploid fibroblasts treated with PDG F, EG F, or growth hormone secrete their own IGF-I . Secreted IGF-I is capable of self-stimulation to promote mitogenesis; anti-IGF-I antibodies block growth hormone stimulation of DNA synthesis.
Fibroblasts and other cells can be transformed with various tumor viruses, oncogenes, chemicals, or radiation. They lose some requirements for exogenous growth factors and produce more of their own as reflected in the decreased serum requirement of some cancer cells [20] [21] [22] [23] . Thus, malignant transformation may result from ectopic production of growth factors, which act at restriction points in the cell cycle [24, 25] .
The ability of some cells to form colonies under anchorage-independent conditions (growth suspended in agar or agarose) is often correlated with their tumorigenicity or state of malignant "transformation" [26] . At least four growth factor activities have been identified which together can reversibly induce this transformed phenotype of murine fibroblasts: PDGF, EGF (or TGFa), IGF-I (or IGF-II, a different somatomedin activity), and an additional growth factor, transforming growth factor / (TGF3) [25, 27, 28] . An important aspect of TGFfl's action as a transforming agent appears to be its induction of basement membrane components, such as collagen and fibronectin [29] , and of the c-sis proto-oncogene [30] . While results using anchorage-independent growth assays suggest that these growth factors are involved in cancer growth control, little direct evidence for an in vivo role in tumor growth has yet emerged. In addition, conclusions drawn from the murine fibroblast model system may not apply to other cancers.
The nature of specific restriction point(s) for epithelial cell cycles is unknown. Normal human mammary epithelial cells require a glucocorticoid such as hydrocortisone, insulin, EGF, PGE, (a prostaglandin), transferrin, and an incompletely defined pituitary component(s) to proliferate in serum-free medium [31] . In contrast to the fibroblast model, TGFJ is a growth inhibitor for many types of normal and malignant epithelial cells, including breast [32, 33] . While some of the same growth factors may facilitate traverse of the cell cycle in both fibroblasts and epithelial cells, control of anchorage-independent growth may involve another growth factor(s). Halper While breast cancer cells may selectively model hormone dependency, their ability to model steps along the pathway toward more malignant behavior is less clear. PMC42, a well-differentiated estrogen-responsive breast cancer cell line, has been recently described. Monoclonal antibodies prepared against surface antigens of this line cross react with intraductal (non-invasive) breast cancer specimens [64, 65] . Numerous estrogen-independent breast cancer lines also exist [47] . While existing cell lines can be sorted according to their estrogen receptor status, nearly all were derived from metastatic sites in patients and are fully malignant in that sense. Somewhat confusingly, virtually all are non-metastatic in nude mice. Thus, controls on metastatic behavior have been difficult to address.
We now turn to evidence that estrogens can directly interact with receptorcontaining breast cancer cells to modulate gene expression and phenotypic properties. We propose that polypeptide growth factors are common mediators of growth control for normal breast epithelium, estrogen-regulated breast cancer, and autonomous hormone-independent breast cancer. By stressing direct effects of estrogens on cancer cells in vitro we do not wish to suggest that growth control of tumors in vivo might not be a much more complex phenomenon resulting from interactions among other cell types, hormones, proteases, and basement membrane components.
In isolated cell cultures of clonal lines of human breast cancer cells, estrogens induce a large number of enzymes and other proteins involved in nucleic acid synthesis. These include DNA polymerase, the c-myc proto-oncogene [66] , thymidine and uridine kinases, thymidylate synthetase, carbamyl phosphate synthetase, aspartate transcarbamylase, dihydroorotase, glucose 6-phosphate dehydrogenase, and dihydrofolate reductase [49, [67] [68] [69] . Physiologic concentration of estrogen stimulates DNA synthesis by both scavenger and de novo biosynthetic pathways. Estrogen regulates thymidine kinase and dihydrofolate reductase at the mRNA level [70, 71 ] . Regulation of thymidine kinase mRNA occurs at the transcriptional level. Increases in global transcription are tightly coupled to estrogen action [72] . The existence of "second message" regulatory systems in the growth induction process is also possible but has not yet been proven. In MCF-7 cells, estradiol-induced stimulation of phosphatidyl inositol turnover to generate diacylglycerol and inositol-triphosphate occurs with an exceptionally long lag time [73] . In other polypeptide growth factor or proteaseinduced model systems, this metabolic effect is rapid (within minutes as opposed to hours for estrogenic effects) and tightly coupled to growth control [74, 75] . Phosphatidyl inositol turnover is associated with stimulation of Ca" fluxes by inositoltriphosphate and of protein kinase C by Ca++ and diacylglycerol. Phosphatidyl inositol could therefore serve as a metabolic mediator of mitogenic effects of estrogen-induced growth factors and/or protease. One potential target for protein kinase C is the Na+/H+ antiporter system. The Na+/H+ antiporter is activated in a number of mitogen-triggered proliferation systems. Inhibition with the antidiuretic amiloride prevents proliferative responses in some systems [76] . Protein kinase C is not an oncogene; however, its expression can lead to disordered morphology of fibroblasts [77, 78] .
Ornithine decarboxylase (ODC) is another intracellular target of estrogen action. ODC is covalently linked to cellular membranes through inositol. This bond is broken by a phosphatidyl inositol-specific phospholipase C, activating the ODC enzyme [79] . ODC activity is associated with induction of proliferation in numerous systems, including breast cancer [80] . The actual contribution to growth control by any of these potential mediators (protein kinase C, ODC, Ca", or Na+/H+ antiporter) remains to be determined.
Progesterone receptor is also induced by estrogen [811] . Estrogen appears to induce the progesterone receptor at the mRNA level [82, 83] . Progestins are growth-inhibitory for human breast cancer while inducing a specific protein of 48 kDa [84] . The presence of the progesterone receptor is generally coupled to functional growth regulation by estrogens in vivo and in vitro. Thus, progesterone receptor content in breast tumors is used as a marker for estrogen and antiestrogen responsiveness of tumors, although exceptions do exist in vitro and in some patient tumors [85] .
Estrogens and antiestrogens alter the cellular synthesis activity and/or secretion of several other proteins whose role in growth control is unclear. These proteins include various plasminogen activators and collagenolytic enzymes. These proteases may contribute to tumor growth and progression by allowing the tumor to digest and traverse encapsulating basement membrane [86] [87] [88] [89] . Proteases may serve additional roles, such as facilitating release of mitogenic growth factors like IGF-I (somatomedin C) from carrier proteins, processing inactive precursor growth factors and proteases to active species [90] , or interacting directly with their own cellular receptors [91, 92] [96, 97] , and 7 kDa (initially identified by detection of an estrogen-induced mRNA species termed pS2) [98, 99] . Four other mRNA species, termed pNR 1-4 [100] , and the cytoplasmic enzyme LDH [101] are also under estrogen regulation. The 52 kDa glycoprotein, one of the major secreted proteins, has cathepsin D-like activity in purified form; it is also mitogenic for MCF-7 cells in vitro [102, 103] . A recent study [104] has suggested that secreted cathepsin D-like activity can release and activate cell-associated transforming growth factor alpha (vide infra). The natures of the 160, 37-39, 52, 24, and 7 kDa proteins are unknown at present, but the 160, 52, and 7 kDa secreted proteins may be disassociated from in vitro estrogen and antiestrogen modulation of MCF-7 cell growth using two MCF-7 clonal variants [105] [106] [107] . These three protein species are decreased by antiestrogen to the same extent in both MCF-7 and LY2, the latter being a stable antiestrogen-resistant variant of MCF-7. In 1-13, an MCF-7 clonal variant which is growth-arrested by physiologic concentrations of estrogen, the same three proteins are induced to the same extent as in MCF-7. These observations suggest that (at least in vitro) a significant alteration in secretion of these major proteins has no effect on growth in LY2 or 1-13. Estrogen induces the cell surface "receptor" or binding protein for laminin in MCF-7 cells [108, 109] . The laminin receptor mediates attachment of cells to basement membrane laminin [88, 89] [24, 114] . TGFa has subsequently been found in many proliferating normal and malignant human tissues. EGF was initially characterized from rodent salivary glands by Cohen [115] but is now known to be more widely expressed in human tissues. The human form was originally known as urogastrone, a placental product. TGFa activity is known to exist in 25 kDa, 21 kDa, and [17] [18] [19] kDa precursor forms [116] and commonly processed to a 7 kDa form. EGF appears to be processed from a very large precursor form (130 kDa) with multiple polypeptide products [117] . EGF, TGFa, and a related protein from vaccinia virus form a functional family of growth factors which apparently utilize the EGF receptor to carry out their many functions [118] .
Several lines of evidence show that breast cancer cells produce TGFa. Cell lines secrete stimulatory factors for MCF-7 and murine 3T3 fibroblast monolayer cultures as well as "transforming growth activity" (TGF). This information has been determined by stimulation of anchorage-independent colonies of rodent NRK and AKR-2B fibroblasts in soft agar culture [119] [120] [121] [122] [123] . The material produced by some breast cancer cells is a 30 kDa molecular weight species of transforming activity for NRK fibroblasts, which comigrates chromatographically with a peak of MDA-231 autostimulatory activity and is the principal species of EGF receptor-competing activity [121, 122] . Antisera specific to TGFa react with this species [124] . Thus, this activity is related to TGFa but appears to be significantly larger than the cloned and sequenced 6 kDa species from transformed rodent fibroblasts [125] . It is not yet certain if this protein is related to the 17-19 kDa TGFa precursor protein observed in transformed fibroblasts [116, 126, 127] , nor is it known if this protein is modified by glycosylation, palmitoylation [116] , or if it is the product of alternative mRNA splicing. The precursor species is thought to be membrane bound in cell lines which express it [116, 126, 127] . It is possible that breast cancer-derived TGFa may be the product of a novel TGFa-related gene. The 30 kDa TGFa-like species is induced by estrogen treatment of estrogen receptor-positive MCF-7, T47D, and ZR-75-1 cells [11, 121, 122, 124, 128, 129] . It increases by two-to fourteenfold depending on cell type and culture conditions. An expected 4.8 Kb TGFa mRNA species has been detected in MCF-7 and other human breast cancer cell lines and breast tumors [123, 130] . This species ranges from low to high estrogen receptor content. No correlation of TGFa mRNA expression was observed with estrogen receptor status; in biopsy samples, at least 70 percent of the adenocarcinomas contained TGFa mRNA [123] .
The significance of TGFa induction and secretion has been further examined. TGFa mRNA is induced in six hours in MCF-7 cells treated with estradiol [123] . Similar observations have been made in hormone-dependent mouse mammary tumors [131] .
Using antibodies directed against either TGFa or its receptor (the EGF receptor), we have noted growth suppression of MCF-7 cells grown as anchorage-independent colonies or as estrogen-stimulated, high-density monolayer cultures [123] . Thus, TGFa has a likely role as an autocrine growth factor in experimental breast cancer. Whether this possibility reflects an artifact of adaption of cells to in vitro culture conditions must await in vivo study. A phase I trial of anti-EGF receptor antibody therapy has been initiated in breast cancer patients [132] . TGFa has also been detected in the urine of patients and nude mice bearing breast and other human tumors [133, 134] . Thus it may provide a marker for tumor burden or disease progression. Detection of urinary TGFa has been complicated by the presence of very high levels of EGF-related growth factors present even in normal control urine [133] .
Insulin and Insulin-Like Growth Factors and Their Receptors
The insulin family of growth factors is a complex group of cross-reacting ligands, further complicated by multiple receptors, and serum-borne binding proteins. Insulin is a two-chain disulfide-linked growth factor, processed from a single gene product (uncleaved, 7.5 kDa size) whose primary site of synthesis is the pancreas. In contrast to insulin, the single-chain, IGF-I, and IGF-II growth factors (somatomedins) are synthesized by many body tissues (including liver). Somatomedins are under different hormonal regulation, particularly growth hormone [135, 136] . Several other growth factors, such as relaxin and lentropin (which controls lens fiber formation) appear to be members of an even larger insulin-related family [1 37 ]. Alternative splicing of mRNA of the insulin-like growth factors (particularly IGF-I) [1 38 ] further contributes to the complexity of members of this diverse family.
Somatomedins or insulin are required both for anchorage-dependent and independent proliferation of fibroblasts. They may also play a role in breast cancer. IGF-I is mitogenic for some breast cancer cells in culture [139, 140] . Using radioimmunoassay, we and others have found that an IGF-I-related species is secreted by all human breast cancer cells examined to date [140, 141] . After partial purification from MCF-7 cell-conditioned medium, this growth factor comigrates on gel exclusion chromatography with authentic human serum-derived IGF-I. Acid ethanol extraction is required partially to disrupt a high molecular weight form of the growth factor. A complex series of IGF-l-cross-reacting mRNA species are also detected with Northern blot analysis, using a cDNA probe to authentic IGF-I [140] ; however, none of these mRNA species are identifiable as authentic IGF-I upon nuclease protection analysis of mRNA [142] . Complex species of IGF-I cross-hybridizing mRNAs have been previously described for the human fetus [143] . Utilizing phenol red-free medium, there is a three-to sixfold induction of IGF-I-like growth factor with estrogens, TGFa, EGF, or insulin treatment [144] . Secretion of IGF-I-related factors is inhibited by antiestrogens, TGF,B, (in phenol red-containing medium), and glucocorticoids. While growth hormone is a strong stimulus for IGF-I production by liver, fibroblasts, and other normal tissues, it is without effect on production of IGF-I-like growth factors by MCF-7 breast cancer cells [144] [145] [146] [147] [148] . IGF-I-related polypeptides are secreted by fibroblasts and smooth muscle and contribute to autocrine growth control in these cell types [146, 148, 149] . It remains to be seen whether IGF-I produced by breast cancer acts primarily on breast cancer itself in an autostimulatory mode or on surrounding stroma to promote chemotaxis and growth. Alternatively, breast cancers may induce surrounding mesenchyme to produce IGF activities which function to stimulate the mesenchyme or the breast epithelium. Recent studies have shown that an antibody which blocks the IGF-I receptor [150] is capable of inhibiting MDAMB-231 breast cancer cloning in vitro [151] and tumor growth in vivo [152] . This finding suggests that importance of an autocrine or paracrine role for growth factors acting through the IGF-I receptor.
Since insulin synergizes with estrogen in promoting growth of breast cancer cell lines in vitro and in vivo in the nude mouse, it is possible that somatomedins principally act by interacting with estrogen to promote breast tumor growth in hormone-dependent cells; their role in hormone-independent cells is even more obscure [153, 154] .
It has also been reported that IGF-II-related gene product(s) are produced by normal and malignant tissue [155] . IGF-II appears to bind to multiple receptors (insulin, IGF-II, and IGF-I). All of these receptors, including the IGF-II receptor, have been detected in human breast cancer [139, 156] as well as in normal breast tissue [157] . While IGF-II interaction with IGF-I receptors may stimulate cellular response, IGF-II receptors may be primarily involved in IGF-II degradation. The IGF-II receptor is a multifunctional protein, previously described as the mannose-6-phosphate receptor for lysosomal enzymes [158, 159] . IGF-I-like mRNA has been recently reported in other human tumors: lung, colon, and liposarcoma [160] [161] [162] . IGF-II has been observed to be overproduced in Wilms tumor [163] . Somatomedins appear to be among the most ubiquitous growth factors, produced by nearly all normal tissues [164] [165] [166] and found in the blood [167] and urine [168] .
Transforming Growth Factor ,B (TGFf)
Transforming growth factor beta (TGFf) is a 25 kDa homodimer initially purified from platelets and various normal tissues. It is required (along with other growth factors) for full induction of the transformed phenotype in fibroblasts. It is also produced autonomously in fibroblasts transformed by oncogenes [169] . TGF3 is a member of a multi-gene family which includes four TGFf3's, Mullerian inhibiting substance, inhibins and activins [170] , a T-cell suppressor factor [171] , and a Drosophila morphogenesis-controlling gene known as decapentaplegic [172] . In contrast to TGFa and many other growth factors, TGF#l is growth-inhibitory and/or differentiating-promoting for most epithelial cells [32, 33, 173] . For example, it inhibits myogenic differentiation [174, 175] . It also inhibits normal hepatocyte growth more extensively than malignant liver cell growth, and it prevents dedifferentiation of other epithelial cell types [176, 177] . In addition, it stimulates differentiated behavior of vascular smooth muscle and normal breast epithelial cultures [178] .
Normal mammary epithelial cells are induced by TGF,B, or TGFb2 to synthesize milk fat globule antigen. In addition, growth of these cells in culture is arrested and the morphology is markedly altered; TGFf, or TGFb2 changes the cobblestone epithelial appearance to an elongated spindle shape [178] . with mitogens or growth inhibitors [184] . TGFj3 activity from antiestrogen-induced MCF-7 cells strongly inhibits the growth of an estrogen receptor-negative cell line MDA-MB-231. This growth inhibition was partially reversed in the presence of a polyclonal antibody directed against native TGF,Bl [184] . Since breast cancers exist as mixtures of estrogen receptor-positive and negative tumor cells [187, 188] and breast cancers may not become TGF,B-unresponsive as they become antiestrogen-unresponsive, TGF,B may act in tumors with such mixed cell populations to make antiestrogen more effective than might otherwise be expected [184] . In LY2 cells, an MCF-7 variant stepwise selected in vitro for antiestrogen resistance, TGFj is no longer induced by antiestrogen, but the cells still retain the TGF,B receptor and response.
Neither the mechanism of TGFf3, induction in MCF-7 cells nor its loss in LY2 cells is fully defined, but it is not at the regulation of steady-state mRNA level. Conversion of a latent form to an active form of TGF3,B may contribute [ 184] . In contrast to other cell types [168, 189] , there is significant active TGFf present in breast cancer-conditioned medium. The biochemical details of the conversion of a secreted inactive to active TG Ff3 remain to be elucidated.
Platelet-Derived Growth Factor (PDGF) PDGF is a heterodimeric protein of approximately 30 kDa, which, as the name implies, is found in high concentrations in platelets. PDGF-like related growth factors are also produced by a variety of transformed murine fibroblast lines and by some human tumors of diverse origins. The v-sis oncogene is related to a PDGF B chain homodimer and can transform PDGF-receptor-expressing cell types [20] . Consequently, PDGF could fulfill an autocrine role in such tumors. In tumors derived from cell types lacking the PDGF receptor, v-sis is not transforming and PDGF presumably functions in a paracrine mode. Paracrine action may stimulate angiogenesis, stromal proliferation (desmoplasia), and chemotaxis and degranulation of monocytes and neutrophils [190] .
Simian sarcoma virus-(SSV) transformed fibroblastic cells provide a model system for the function of PDGF in responsive cell types. In this system, the PDGF-B chain-related protein encoded by the virus forms a homodimer and is sometimes secreted by the cell. Antibodies directed against PDGF have been reported to exert antiproliferative and antitransforming activity [190] ; however, in many instances the PDGF is largely cell-associated and presumably already bound to its receptor. Thus, anti-PDGF antisera have been only partially effective as antiproliferative reagents [191] . The subcellular origin or fate of PDGF remains to be fully characterized; however, immunoreactive PDGF has been observed in the cell nucleus [192] in SSV-transformed cells. PDGF is known to encode a short peptide sequence which is capable of directing the molecule across the nuclear pore complex [193] . Thus, PDGF may exert autocrine growth control through both intracellular and extracellular mechanisms of action [ 194] .
Many breast cancer cell lines secrete a PDGF-related activity detected by anchorage-dependent growth stimulation of mouse 3T3 fibroblasts in the presence of platelet-poor plasma. This fact is known as a "competency" assay for early mitogenic signals [195] . 28 kDa and 16 kDa species were observed by immunoprecipitation of metabolically labeled MCF-7, MDA-MB-231, and other breast cancer cell extracts and medium. The 28 kDa species (the unreduced form) was biologically active after elution from non-reducing SDS-polyacrylamide gels, and its activity was blocked with anti-PDGF antiserum. Upon examination of poly A-selected mRNA from either cell line, transcripts of both PDGF-A and B chains are observed [196] [197] [198] [199] . A and B chains are widely expressed in breast cancer and other cell lines [200] [201] [202] [203] . While the B chain is homologous to the v-sis oncogene, the A chain is not known to have a retroviral oncogene homologue. The A and B chains share substantial sequence homology to each other [204] , and the A chain shows evidence of alternative mRNA splicing [205] . It [212, 213] . FGF is required for normal mouse mammary cells to proliferate in culture. It is present in pituitary extract used for culture of mouse and human mammary myoepithelial and epithelial cells [214, 215] . FGF is also a potent angiogenic substance [210] . The FGF family of peptides is characterized by a binding site for heparin [206] . This property has facilitated purification and may allow for strategies to interrupt or otherwise modulate FGF action through binding of various polyanionic substances such as suramin to this site [216] . bFGF does not possess a signal peptide in its primary sequence [217] , giving rise to hypotheses for unusual secretory pathways, including intracellular binding to heparin proteoglycan and secretion as a part of the basement membrane [206] .
Uncertainty exists as to the principal target of FGF in the normal mammary gland. Rudland has proposed that effects are restricted to myoepithelium and stroma [218] , but Karey and Sirbasku have claimed that MCF-7 and T47D human breast carcinoma cells respond [219] . We have not been able to confirm this result. A 60 kDa, heparin-binding FGF-related molecule is produced by human breast cancer cells in culture. Its function could include autocrine and paracrine effects [220] .
Pituitary Hormones, Other Steroids, and Growth Factors Growth factors and/or estrogen probably act in concert with other systemic mitogens in vivo to promote tumor growth. Shiu and co-workers have isolated a pituitary-derived activity which potentiates the mitogenic effects of estradiol on MCF-7 cells [221] . One pituitary factor has already been identified as IGF-II [222] . In addition, pituitary-derived GnRH may also directly interact with breast cancer to inhibit its proliferation [223] , while prolactin is stimulatory for some cell lines [40] .
MCF-7 cells in monolayer culture are growth-regulated by a variety of lipid-soluble hormones in addition to estrogen. These hormones include glucocorticoids, iodothyronines, androgens, and retinoids [224] . MCF-7 cells have receptors but are not growth-stimulated by progesterone or vitamin D [225] [226] [227] . Progesterone induces a specific protein [226] and can be growth-inhibitory in vitro [228] . Other inhibitory hormones include somatostatin [229] , interleukins 1 and 6, tumor necrosis factor (TNF), and interferon [230] . Receptors and metabolic effects, but little cellular growth response, have been demonstrated for other hormones, such as growth hormone, glucagon, and calcitonin [227] . Finally, transferrin, a serum iron delivery molecule, is required for proliferation of normal and malignant mammary cells [231] ; its receptor is increased in estrogen-independent breast cancer compared to estrogendependent breast cancer [232] .
The multiplicity of growth modulatory hormones for in vitro breast cancer systems suggests the possibility that many serum-borne or locally produced modulators of growth may play important regulatory roles in vivo. Alternatively, or additionally, growth factors with a similar spectrum of activities could be elaborated by the breast cancer cells themselves. While on the one hand, this large number of regulatory molecules emphasizes the potential complexity of growth control of breast cancer, it can also be seen as emphasizing the diverse number of targets for biological therapy. A variety of strategies including anti-ligand and anti-receptor antibodies, receptorblocking peptides, drugs which alter receptor ligand interaction, and anti-sense RNA strategies all have promise for novel approaches to the problem of breast cancer.
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